Objective:To investigate the intervention effect of Shenqi Wan on dimethylnitrosamine (DMN)-induced liver fibrosis in rats. Method: DMN (10 mg·kg-1) was administrated intraperitoneally to DMN-treated rats for the first three days per week for 4 weeks

at the second weekend

DMN rats were randomly divided into Shenqi Wan group(n=10)and modle group(n=10). At the first day of the third week

both groups continued to receive weekly DMN treatment for another 2 weeks in addition to daily administration of Shenqi Wan. At the end of the experiment

all rats were sacrificed. Liver tissue specimens and serum were remained to observe liver function

liver tissue hydroxyproline (Hyp) and liver histopathological changes of rats

expression changes of liver tissue hepatocyte growth factor (HGF)

smooth muscle actin (alpha-SMA) mRNA were observed by real-time quantitative PCR. Result: Liver dysfunction was based on DMN modeling for four weeks

compared with normal group

the serum aspartate aminotransferase (ALT) and alanine aminotransferase (AST) activity and total bile acid(TBA) content in the fourth week model group were significantly increased (P<0.01)

serum albumin (ALB) were significantly decreased (P<0.01)

liver hydroxyproline content was significantly increased 4.58 fold (P<0.01)

HGF mRNA expression was decreased significantly (P<0.01)

α-SMA mRNA levels were significantly increased (P<0.01). Compared with model group

serum ALB content in Shenqi Wan group was significantly increased

the serum aspartate aminotransferase (ALT) and alanine aminotransferase (AST) activity and TBA content were significantly decreased. Shenqi Wan could significantly reduce liver tissue hydroxyproline content (P<0.05). Shenqi Wan could significantly reduce α-SMA mRNA expression (P<0.01)

and elevated HGF mRNA level (P<0.05). Conclusion: Shenqi Wan has a good effect for liver fibrosis and provides an experimental basis for liver disease treatment from kidney.